Biologics Safety: Stronger Pharmacovigilance For First-In-Class BLAs Urged In JAMA Report
Over 23 percent of biologics were subject to post-approval “Dear Doctor” communications or black box warnings during a 12-year period, study finds.
Over 23 percent of biologics were subject to post-approval “Dear Doctor” communications or black box warnings during a 12-year period, study finds.